UPAR Ultra Risk Parity ETF
Limited financial coverage for UPAR.
Not enough data to compute a meaningful composite — typical for foreign-listed ADRs, recent IPOs, or thinly-covered small caps. Live quote, chart, and any available stats still render below.
Price Chart
About the company
This ETF utilizes a risk parity investment approach comparable to RPAR, but it is structured to aim for enhanced returns by accepting an amplified risk profile. Its investment strategy involves prudently spreading capital across four distinct market segments: corporate stocks, raw materials, government debt instruments, and Treasury Inflation-Protected Securities (TIPS).
- IPO
- 2022
- HQ
- Milwaukee, WI, US
Get TickerSpark's AI analysis on UPAR
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $57.30M
- Div Yield
- 3.43%
- 52W High
- $17.71
- 52W Low
- $14.77
- 50D MA
- $15.90
- 200D MA
- $16.32
- Beta
- 1.54
- RSI (14)
- 36
- Avg Volume
- 9.47K
No earnings-call transcripts are available for UPAR yet.
- Free Float
- 0.0%
- Shares Outstanding
- 3.81M
- Float Shares
- 0
of shares held by institutions
4 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Mai Capital Management | 2.06M | ▲ 2.06M |
| 46 Peaks LLC | 48.10K | ▼ 2.94K |
| Brookwood Investment Group LLC | 12.52K | ▲ 432 |
| Fermata Advisors, LLC | 11.06K | ▲ 69 |
| Zega Investments, LLC | 10.24K | ▲ 10.24K |
| Farther Finance Advisors, LLC | 8.06K | ▲ 8.06K |
| Td Waterhouse Canada Inc. | 2.00K | ▲ 2.00K |
| Fiduciary Financial Advisors | 726 | ▲ 726 |
Our UPAR coverage
Recent articles, reports, and earnings notes.
No research on UPAR yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate UPAR report →NorthStar Medical Radioisotopes Provides Updates on Corporate Progress and Upcoming Milestones
businesswire.com · Apr 3
Conjugated Monoclonal Antibodies Global Market Research Report 2022 - ResearchAndMarkets.com
businesswire.com · Jun 16
Conjugated Monoclonal Antibodies Global Market Report 2021: COVID-19 Growth and Change to 2030 - ResearchAndMarkets.com
businesswire.com · Jan 7
Toroso Launches Leveraged ETF for Investors Seeking More Upside
etftrends.com · Jan 4
Real-Time Monitoring of Melanoma Cell Invasion Helps Scientists Elucidate Key Regulators of Metastasis
businesswire.com · Dec 18
Onxeo Grants Exclusive Worldwide License of Validive® Developed for the Treatment of Oral Severe Mucositis to Monopar Therapeutics
businesswire.com · Sep 13
Onxeo concède à Monopar Therapeutics une licence mondiale exclusive de Validive®, développé dans le traitement de la mucite orale sévère
businesswire.com · Sep 13
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.